Molecular therapy for Pulmonary Hypertension (PAH): Endothelin-1 inhibits pulmonary hypertension via induction of PDLIM5, 10/February/2015, 23.25

Molecular therapy for Inflammatory Bowel disease (IBD): p63 preserves the functions of Beclin 1 and ATG5 and decreases tissue injury in inflammatory bowel disease (IBD) via down regulation of its target gene, 10/February/2015, 23.22
February 10, 2015
Therapeutic insights into arterial ageing: p63 inhibits Vascular Smooth Muscle Cells Senescence and the expression of senescence-associated pro-inflammatory proteins via down regulation of its target gene, 10/February/2015, 23.29
February 10, 2015
Show all

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Significance: This study suggests, for the first time, that Endothelin-1, by suppressing the expression of its target gene, it may increase the expression of PDLIM5. Thereby, it may inhibit pulmonary hypertension. Together, pharmacological formulations encompassing “Endothelin-1 or its activators may be used to treat pulmonary arterial hypertension (PAH).

Amount: $ 300*

Undisclosed information: How Endothelin-1  increases the expression of PDLIM5

To citeBoominathan, Molecular therapy for Pulmonary Hypertension (PAH): Endothelin-1 inhibits pulmonary hypertension via induction of PDLIM5, 10/February/2015,  23.25,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Comments are closed.